Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab in patients with unresectable hepatocellular carcinoma (HCC).

oxaliplatin
neutrophil count
  • 0 views
  • 22 Aug, 2021
  • 1 location
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)

Primary Objective: To confirm the safety and feasibility of canakinumab and spartalizumab (PDR-001) administered using a standard dose / schedule in the neo-adjuvant setting in renal cell carcinoma Secondary Objectives: To assess the immune response to combination canakinumab and spartalizumab To assess anti-tumor activity as measured by pathologic downstaging

clear cell renal cell carcinoma
nephrectomy
neutrophil count
carcinoma
  • 1 views
  • 25 May, 2022
Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM)

This trial is designed as a unicenter, single arm phase II trial. The aim of the trial is to test whether prognosis of high-risk Aggressive B cell Lymphoma (ABCL) patients who are in complete remission (CR) post immunochemotherapy can be improved by 2year nivolumab maintenance therapy. Participants will be recruited …

anthracyclines
beta human chorionic gonadotropin
neutrophil count
remission
blood transfusion
  • 2 views
  • 04 Feb, 2022
  • 1 location
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

lung adenocarcinoma
systemic therapy
mpnst
measurable disease
cancer chemotherapy
  • 34 views
  • 27 Jul, 2022
  • 19 locations
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

  • 1 views
  • 28 Feb, 2022
  • 12 locations
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma

To explore the objective response rate and safety of toripalimab combined with Gemox in the first-line treatment of progressive, metastatic or unresectable advanced ICC.

measurable disease
oxaliplatin
gemcitabine
metastasis
  • 0 views
  • 25 Jul, 2021
  • 1 location
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. At …

EGFR
lung cancer
lung carcinoma
diabetes
bronchoscopy
  • 0 views
  • 08 Jul, 2022
  • 2 locations
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

The purpose of this study is to explore the efficacy and safety of toripalimab combined with anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell Lung Cancer.

EGFR
proto-oncogene tyrosine-protein kinase ros
cancer chemotherapy
lung carcinoma
ROS1
  • 0 views
  • 06 Dec, 2021
  • 1 location
MRD-guided Treatment in NPM1mut AML Patients (PEMAZA)

Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).

anthracyclines
residual tumor
cell transplantation
cytarabine
remission
  • 2 views
  • 29 Jul, 2022
  • 11 locations